Your SlideShare is downloading. ×
0
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010

406

Published on

SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010 …

SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
For additional information, please visit http://www.sqidiagnostics.com

Published in: Investor Relations
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
406
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. 2009 AGM, March 30, 2010
  • 2. 2
    Safe harbour statement
    This presentation may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including comments predicting the timing of financings, strategic partnering, regulatory actions, or the capabilities of the platform. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company’s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement. This presentation should not be considered an official disclosure document of the Company.
    This document is for information purposes only and is not intended to be used to solicit the sale of securities.
    SQI Diagnostics™ Inc. PRIVATE and CONFIDENTIAL – NOT FOR DISTRIBUTION without the express written consent of SQI Diagnostics Inc.
  • 3. Multiplexing, Miniaturization and Automation.
    Analyzemultiple biomarkers,
    Deliveraccurate patient results in less time,
    Reduce labor, and
    Increase profits…
    All in One Drop
    SQI Diagnostics
    3
  • 4. SQiDworks™ – the first fully-automated multiplexing workstation for diagnostic microarrays.
    IgXplex™
    Patented Microarray Assay
    providing 3 strategic customers benefits
    Confidence, Profit and Growth
    4
  • 5. SQiDworks & RA Assay
    5
    United States
    European Union
    cleared for sale in
    Canada
  • 6. Value creation
    6
    1st ID panels filed
    Complete AI panels
    SQiDmanlaunch
    U.S. market launch
    Scale up capital
    FDA clearance
    Technology investment
    Health Cdaapproval
    RA panel validation
    Fully automatedsystem
    A-G-M calibration
    2005
    2006
    2007
    2008
    2009
    2010
    2011
    Printing optimization
    Automated arrayscanning
    Surface optimization
    Multipexed array demo
    Microarray concept
  • 7. 7
    MultiplexingWhy?
  • 8. 8
    Current multiple biomarker testing is labour intensive
    SINGLE
    biomarker testing
    MULTIPLE
    biomarker testing
    1test
    1unit of reagents
    1unit of labour
    1result
    6tests
    6units of reagents
    6units of labour
    6results
    No economies of scale for multiple testing!
  • 9. Study of 324 clinical laboratories by Chi Solutions in 2008
    8.9% Send Outs
    6.0% Other
    57.9%Labor & Benefits
    2.4% Depreciation
    1.5% Repair
    0.6% Lease/Rental
    20.9%Supplies
    9
  • 10. Evolution with Purpose: 4th Generation
    10
    SQI Diagnostics’ IgXplex:
    The Next Generation Immunoassay
  • 11. 11
    TechnologyPlatform and Assay
  • 12. Load
    Go
    &
    Productivity!
    Complete automation of all assay steps
    Integrates with standard lab automation systems
    Throughput: 222 patients / run
    ~700 patient results / hour .
    12
  • 13. Load
    Go
    &
    Productivity!
    13
  • 14. 14
    IGXPLEX™
    1 well
    1 patient Multiple Results
    • Multiplexing at 2 levels – antigen & antibody class (IgXPLEX™)
    • 15. Industry-standard 96 well format
    • 16. 74 patients per consumable 12plex’d = 888 biomarker results per consumable
    • 17. Up to 12 biomarkers tested quantitatively and 24 screening
    • 18. 23 within well, 72 within plate
    multiple tests / multiple patients
    results with < one unit of labour
  • 19. 15
    BusinessValue Proposition
  • 20. 16
    SQI Diagnostics biomarker testing
    74 patients | 9 biomarkers
    requiring 1 “plate”
    Traditional manual biomarker testing
    74 patients | 9 biomarker requiring 18 “plates”
    SQI Diagnostics value proposition: dramatic economies of scale
    Automated micro array technology powering a technology shift…
    ~ 4 minutes perbiomarker Technician ‘hands-on’ time
    ~ 3 secondsper biomarkerTechnician ‘hands-on’ time
    80 X
    Reduction
  • 21. 17
    Profit increases by up to $40 per patient in 9-plex panel
    Current Method
    IgX-Plex
    18 microtiter plates required
    36 minutes / patient
    0.3 minutes / patient
    Costs
    Total: $42.55
    Total: $82.58
    Total: $82.58
  • 22. Sales Funnel
    Labs in USA
    14,000
    “Current” Target Market
    300
    60
    Current Focus Accounts
    20
    Meetings Completed/Scheduled
    6–10
    Target Installs for 2010
    Completed Validation (to date)
    1
    18
    18
    All in One Drop
  • 23. 19
    Current Product Pipeline
    Candidate Panels
    Insight
    Proof of
    Concept
    Assay
    Develop
    Automation
    Verification
    Multisite Validation
    Regulatory Submission
    RA v2
    Vasculitis-4x
    Auto Hep
    Renal
    Food Intolerance
    Lupus-12x
    Celiac-4x
    IBD-8x
    APS-9x
    Thyroid-3x
    Customer
    Delivery
    BOTX-3x
    Infliximab(RUO)-3x
    Six-Month Internal Development Timeframe
  • 24. Goals for 2010
    • Three assays submitted to FDA
    • 25. FDA Clearance for at least one New Product
    • 26. Two OEM products delivered
    • 27. Multiple Health Canada Approvals
    • 28. Six Customer installation Sites
    • 29. Customer Revenue
    20
  • 30. 21
    Company overview
    Headquarters: Toronto, Ontario
    Founded: 1999
    Symbol: TSX.V SQD
    Financial data :
    27,193,000 shares issued and outstanding
    32,279,000 shares on a fully diluted basis
    $26.5 million raised since 2004
    $8.543 million current assets as at December 31, 2009
    Cash in place through 2011
    Cash burn rate of ~$625,000 per month
  • 31. Cover to be like annual report
    2009 AGM, March 30, 2010

×